Biological agents for controlling excessive scarring

American Journal of Clinical Dermatology

Volumn 11, Issue SUPPL. 1, 2010, Pages 31-34

  Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BIOLOGICAL PRODUCT; ETANERCEPT; IMIQUIMOD; PLACEBO; RECOMBINANT INTERLEUKIN 10; TACROLIMUS; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTROPHIC SCAR; IMMUNE RESPONSE; IN VITRO STUDY; KELOID; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW; SCAR FORMATION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; CICATRIX, HYPERTROPHIC; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2B; KELOID; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954273709     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/1153419-S0-000000000-00000     Document Type: Review

References (30)

1. Berman B, Villa AM, Ramirez CC. Novel opportunities in the treatment and prevention of scarring. J Cutan Med Surg 2004; 8 Suppl. 3: 32-6
2. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274-85
3. Berman B, Flores F. The treatment of hypertrophic scars and keloids. Eur J Dermatol 1998;8:591-5
4. Saed GM, Ladin D, Olson J, et al. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol 1998;134:963-7
5. Ladin DA, Hou Z, Patel D, et al. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen 1998;6:28-37
6. Berman B, Patel JK, Perez OA, et al. Evaluating the tolerability and efficacy of etanercept compared to triamcinolone acetonide for the intralesional treatment of keloids. J Drugs Dermatol 2008;7:757-61
7. Calabrese F, Carturan E, Chimenti C, et al. Overexpression of tumor necrosis factor (TNF) alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol 2004;17:1108-18
8. Lundblad LK, Thompson-Figueroa J, Leclair T, et al. Tumor necrosis factoralpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005;171:1363-70
9. Navarro JF, Milena FJ, Mora C, et al. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006;26:562-70
10. Stassi G, De Maria R. Autoimmune thyroid disease: new modelsofcell death in autoimmunity. Nat Rev Immunol 2002;2:195-204
11. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21:694-702
12. Brysk MM, Selvanayagam P, Arany I, et al. Induction of apoptotic nuclei by interferon-gamma and by predesquamin in cultured keratinocytes. J Interferon Cytokine Res 1995;15:1029-35
13. Jacob SE, Berman B, Nassiri M, et al. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol 2003; 149 Suppl. 66: 62-5
14. Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch Dermatol 1990;126:1295-302
15. Larrabee Jr WF, East CA, Jaffe HS, et al. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg 1990;116:1159-62
16. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997;37:755-7
17. Novak N, Yu CF, Bieber T, et al. Toll-like receptor 7 agonists and skin. Drug News Perspect 2008;21:158-65
18. Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol 2007; 157 Suppl. 2: 8-13
19. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47 (4 Suppl.) : S209-11
20. Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. J Med Assoc Thai 2007;90:1363-7
21. Stashower ME. Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg 2006;32:380-6
22. Berman B, Viera MH, Amini S, et al. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg 2008;19:989-1006
23. Ferguson MW, O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004;359:839-50
24. Durani P, Occleston N, O'Kane S, et al. Avotermin: a novel antiscarring agent. Int J Low Extrem Wounds 2008;7:160-8
25. Gordon A, Kozin ED, Keswani SG, et al. Permissive environment in postnatal wounds induced by adenoviral-mediated overexpression of the anti-inflammatory cytokine interleukin-10 prevents scar formation. Wound Repair Regen 2008;16:70-9
26. Peranteau WH, Zhang L, Muvarak N, et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol 2008;128:1852-60
27. Renovo. Prevascar® phase II results. Renovo announces positive phase II efficacy trial results for Prevascar® [Press release 17 Apr. 2007]. [cited 2009 March 29]; Available from: http://www.renovo.com/itemdetails.asp?c- id=31&news-id=29
28. Kim A, DiCarlo J, Cohen C, et al. Are keloids really "gli- loids"?: High-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001;45:707-11
29. Macaron NC, Cohen C, Chen SC, et al. gli-1 Oncogene is highly expressed in granulomatous skin disorders, including sarcoidosis, granuloma annulare, and necrobiosis lipoidica diabeticorum. Arch Dermatol 2005;141:259-62
30. Berman B, Poochareon V, Villa AM. An open-label pilot study to evaluate the safety and tolerability of tacrolimus ointment 0.1% for the treatment of keloids. Cosm Dermatol 2005;18:399-404